Press "Enter" to skip to content

Nation of Georgia gets an Approval for Emergency Use of ZYESAMI

The Prime Minister and Minister of Health of the Republic of Georgia have approved an Emergency Use Authorization for intravenous ZYESAMI (aviptadil) for the treatment of Critical COVID-19, according to NRx Pharmaceuticals, a clinical-stage global biopharmaceutical business. ZYESAMI (aviptadil) has been approved for emergency use in  by NRx Pharmaceuticals.

Georgia doctors are noticing considerable daily increases in COVID-19 cases, hospitalised patients, and notably, patients in hospital intensive care units, as a result of the regulatory approval. Prof. Jonathan Javitt, MD, MPH, Chief Executive Officer and Chairman of the Board of NRx, said, “Lead investigators from our ZYESAMI™ clinical trials are on their way to the Nation of  and will be on the ground there within 24 hours to start teaching physicians how to administer ZYESAMI™ to some of the sickest of COVID patients.”

Medical personnel in Georgia are working around the clock to keep patients breathing during the newest wave of COVID-19, which was caused by the delta variant. Dr. Javier Perez-Fernandez, a critical care pulmonologist in Miami, Florida, and a key investigator in the Phase 2b/3 clinical trial of intravenous ZYESAMI (aviptadil), is leading a team of physicians travelling to to instruct colleague clinicians on how to give ZYESAMI and its effects.

Twenty of Georgia finest critical care physicians are among the first Georgia physicians to be trained in giving ZYESAMI. The first doses of ZYESAMI will arrive in within 24 hours, and talks with the Ministry of Health are underway to give ZYESAMI to suffering from Critical COVID-19. ZYESAMI (aviptadil) is a synthetic form of Vasoactive Intestinal Polypeptide (VIP), which was first discovered in 1970 by the late Prof. Sami Said, and is named after him. It was originally purified from the digestive tract, despite the fact that it is largely concentrated in the lungs.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *